The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI.
URI
metastases
miR-598
ovarian cancer
proliferation
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
29 Mar 2019
29 Mar 2019
Historique:
received:
16
05
2018
accepted:
02
12
2018
entrez:
22
1
2019
pubmed:
22
1
2019
medline:
22
1
2019
Statut:
epublish
Résumé
Unconventional prefoldin RPB5 interactor (URI, or RMP, a member of the prefoldin family of molecular chaperones) exhibits oncogenic activity in several types of cancer, including ovarian cancer. However, the underlying regulatory mechanism in ovarian cancer remains unclear. MicroRNAs (miRNAs) negatively regulate gene expression, and their dysregulation has been implicated in tumorigenesis. To elucidate the role of miRNAs in URI-induced ovarian cancer, miR-598 and URI were overexpressed in the SKOV3 ovarian cancer cell line. The CCK8 kit was used to determine cell proliferation, and the Transwell assay was used to measure cell invasion and migration. RT-PCR and western blotting were used to analyze the expression of miR-598 and URI, and the luciferase reporter assay was used to examine the interaction between miR-598 and URI. Nude mice were used to characterize the regulation of tumor growth
Identifiants
pubmed: 30662936
doi: 10.1016/j.omto.2018.12.002
pii: S2372-7705(18)30037-8
pmc: PMC6325085
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9-15Références
Science. 2003 Nov 14;302(5648):1208-12
pubmed: 14615539
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Mol Cell Biol. 2004 Oct;24(19):8556-66
pubmed: 15367675
Nature. 2005 Feb 17;433(7027):769-73
pubmed: 15685193
Science. 2008 Mar 28;319(5871):1789-90
pubmed: 18369137
J Clin Oncol. 2009 Dec 1;27(34):5848-56
pubmed: 19884536
Annu Rev Pharmacol Toxicol. 2011;51:25-43
pubmed: 20809797
J Biol Chem. 2011 Apr 1;286(13):11865-74
pubmed: 21310960
Cancer Cell. 2011 Mar 8;19(3):317-32
pubmed: 21397856
Int J Clin Exp Pathol. 2013;6(4):669-77
pubmed: 23573313
Cell Death Dis. 2014 Mar 13;5:e1126
pubmed: 24625985
Exp Mol Pathol. 2015 Feb;98(1):47-54
pubmed: 25527175
Am J Cancer Res. 2015 Mar 15;5(4):1353-67
pubmed: 26101702
Am J Cancer Res. 2015 Jun 15;5(7):2320-9
pubmed: 26328264
Oncotarget. 2016 May 17;7(20):29635-47
pubmed: 27105489
Oncol Lett. 2016 Jul;12(1):269-274
pubmed: 27347136
J Biol Chem. 2016 Dec 2;291(49):25516-25528
pubmed: 27780869
Exp Cell Res. 2017 Mar 1;352(1):104-112
pubmed: 28161537
Mol Med Rep. 2018 Feb;17(2):2991-2997
pubmed: 29257251
Onco Targets Ther. 2018 May 17;11:2911-2923
pubmed: 29844688
Mol Cell Biol. 1998 Dec;18(12):7546-55
pubmed: 9819440